TC-N201(TCRCure)

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameTC-N201(TCRCure)
Drug Alias NameTC-N201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-NY-ESO-1Anti-PD-1
TargetsCancer/testis antigen 1Programmed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTcrcure Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesTcrcure Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A